Klinisk Biokemi i Norden · 4 2016
| 13
9. Ueland PM, Midttun O, Windelberg A, Svar-
dal A, Skålevik R, Hustad S. Quantitative
profiling of folate and one-carbon metabo-
lism in large-scale epidemiological studies
by mass spectrometry. Clin Chem Lab Med
2007;45:1737-45.
10. Refsum H, Smith AD, Ueland PM, Nexo E,
Clarke R, McPartlin J, et.al. Facts and recom-
mendations about total homocysteine deter-
minations: an expert opinion. Clin Chem
2004;50:3-32.
11. Hvas AM, Nexø E. Diagnosis and treatment
of vitamin B12 deficiency--an update. Hae-
matologica 2006;91:1506-12.
12. Fedosov SN. Biochemical markers of vitamin
B12 deficiency combined in one diagnostic
parameter: the age-dependence and associa-
tion with cognitive function and blood hemo-
globin. Clin Chim Acta 2013;422:47-53.
13. Fedosov SN, Brito A, Miller JW, Green R,
Allen LH. Combined indicator of vitamin
B12 status: modification for missing biomar-
kers and folate status and recommendations
for revised cut-points. Clin Chem Lab Med
2015;53:1215-25.
14. Hvas AM, Morkbak AL, Hardlei TF, Nexø E.
The vitamin B12 absorption test, CobaSorb,
identifies patients not requiring vitamin B12
injection therapy. Scand J Clin Lab Invest
2011;71:432-8.
15. Nielsen MJ, Rasmussen MR, Andersen CB,
Nexø E, Moestrup SK. Vitamin B12 transport
from food to the body's cells--a sophisticated,
multistep pathway. Nat Rev Gastroenterol
Hepatol 2012;9:345-54.
16. Hvas AM, Morkbak AL, Nexo E. Plasma
holotranscobalamin compared with plasma
cobalamins for assessment of vitamin B12
absorption; optimisation of a non-radioactive
vitamin B12 absorption test (CobaSorb). Clin
Chim Acta 2007;376:150-4.
17.
/ blod-
prover-og-biokemi/analysefortegnelse/ hospi-
tal, Pt-Vitamin B12-absorption gruppe.
18. Arendt JF, Farkas DK, Pedersen L, Nexo E,
Sørensen HT. Elevated plasma vitamin B12
levels as a marker for cancer: A popula-
tion- based cohort study. J Natl Cancer Inst
2013;105:1799-805
19. Arendt JF, Nexø E. Unexpected high plasma
cobalamin: proposal for a diagnostic strategy.
Clin Chem Lab Med 2013;51:489-96.
20. Lildballe DL, Nguyen KQ, Poulsen SS, Nielsen
HO, Nexo E. Haptocorrin as marker of disease
progression in fibrolamellar hepatocellular
carcinoma. Eur J Surg Oncol 2011;37:72-9.
21. Morkbak AL, Hvas AM, Milman N, Nexø
E. Holotranscobalamin remains unchanged
during pregnancy. Longitudinal changes of
cobalamins and their binding proteins during
pregnancy and postpartum. Haematologica
2007;92:1711-2.
22. Carmel R. Haptocorrin (transcobalamin
I) and cobalamin deficiencies. Clin Chem
2007;53:367-8.
23. Sobczyńska-Malefora A, Pangilinan F, Plant
GT, Velkova A, Harrington DJ, Molloy AM,
Brody LC. Association of a transcobalamin II
genetic variant with falsely low results for the
holotranscobalamin immunoassay.Eur J Clin
Invest 2016;46:434-9.
24. Keller P, Rufener J, Schild C, Fedosov SN,
Nissen PH, Nexø E. False low holotrans-
cobalamin levels in a patient with a novel
TCN2 mutation. Clin Chem Lab Med 2016.
doi: 10.1515/cclm-2016-0063. [Epub ahead of
print]
25. Carmel R, Agrawal YP. Failures of cobalamin
assays in pernicious anemia. N Engl J Med
2012;367:385-6.
26. Greibe E, Arendt J, Nexø E. More on failures
of cobalamin assays in pernicious anemia. N
Engl J Med 2012;367:1569-70.
27. Watkins D, Rosenblatt DS. Lessons in biology
from patients with inborn errors of vitamin
B12 metabolism. Biochimie 2013;95:1019-22.
28. Nissen PH, Nordwall M, Hoffmann-Lücke E,
Sorensen BS, Nexø E. Transcobalamin defi-
ciency caused by compound heterozygosity
for two novel mutations in the TCN2 gene: a
study of two affected siblings, their brother,
and their parents. J Inherit Metab Dis 2010;33
Suppl 3:S269-74.
29.
